NCT06272409尚未招募3 期
Phase III, Multicenter, Double-blind, Planned, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children Aged Between 6 and 11 Years
EMS0 个研究点目标入组 318 人开始时间: 2025年2月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 318
- 主要终点
- To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years.
详细描述
- double-blind, superiority, parallel group trial.
- Experiment duration: 05 days.
- 03 visits (days 0, 5 and 28).
- Efficacy will be evaluated for persistent allergic rhinitis based on Global improvement in nasal symptoms score
- Adverse events evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to confirm voluntary participation and agree for all the purposes of the test, signing and dating the Term of Free and Informed Assent (TALE), signed by the Free and Informed Consent Form (TCLE) by responsible;
- •Age ≥ 6 years and ≤ 11 years on the day of signing the TALE and the TCLE by the person responsible;
- •Diagnosis of moderate to severe persistent allergic rhinitis (PAR) according to the criteria of Allergic Rhinitis and its Impact on Asthma (ARIA);
- •Presence of sensitization to aeroallergens confirmed by positive result to the immediate reading skin test (PRICK test) and/or the presence of specific IgE to the test radioallergoabsorbent (RAST);
- •Symptom intensity score "nasal obstruction" ≥ 2 points.
- •Total nasal symptoms score (TNSS) ≥ 8 points.
排除标准
- •Use of prednisolone or other oral or parenteral corticosteroid in the seven (07) days prior to inclusion;
- •Use of H1 antihistamine, anti-leukotriene and decongestant topic in the seven (07) days prior to inclusion;
- •Use or indication for the use of antibiotics at the screening visit and randomization;
- •Presence of adenoid hypertrophy or anatomical disorders known obstructive disorders (e.g. septal deviation) that may be held responsible for nasal obstruction, at the discretion of the investigator;
- •Diagnosis of severe or uncontrolled asthma;
- •Allergy to desloratadine, prednisolone or any other component of the formulation of investigational products (PSIs);
- •Presence of systemic fungal infection;
- •Presence of any uncontrolled infection;
- •Presence of any clinical observation finding (evaluation clinical/physical) or laboratory condition that is interpreted by the investigator physician as a risk to participation in the trial clinical or presence of serious uncontrolled disease(s);
- •Participants who are pregnant or breastfeeding;
- •Participation in clinical trial protocols in the last 12 (twelve) months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator believes that there may be direct benefit to the participant.
研究组 & 干预措施
DEP114
Experimental
DEP114 administered once (01) time a day, by morning, for 5 (+2) days.
干预措施: DEP114 (Drug)
DESLORATADINE
Active Comparator
Desloratadine administered once (01) time a day, by morning, for 5 (+2) days.
干预措施: Desloratadine 0.5 MG/ML (Drug)
结局指标
主要结局
To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment.
时间窗: 5 days
Global improvement in nasal symptoms (absolute variation in total nasal symptoms score obstruction, runny nose, itching and sneezing, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) five days after the start of treatment.
次要结局
- Evaluate the efficacy of DEP114 to relieve coryza present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.(3 and 5 day)
- Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the perception of the person responsible for the participant.(5 day)
- To evaluate the effectiveness of DEP114 in relieving nasal symptoms of moderate to severe persistent allergic rhinitis in children, throughout the treatment.(1-5 days)
- Evaluate the efficacy of DEP114 to relieve nasal obstruction present in moderate to severe persistent allergic rhinitis in children through the treatment.(1-5 days)
- Evaluate the efficacy of DEP114 to relieve nasal itching present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.(3 and 5 day)
- Evaluate the efficacy of DEP114 to relieve sneezing present in persistent allergic rhinitis moderate to severe in children, three and five days after the start of treatment.(3 and 5 day)
- Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the investigator's perception.(5 day)
研究者
相似试验
尚未招募
3 期
Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary DysmenorrheaPrimary DysmenorrheaNCT06268054EMS78
尚未招募
不适用
Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain in Primary Dysmenorrhea: a Pilot StudyPrimary DysmenorrheaNCT06555549EMS60
已完成
2 期
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)Mild-moderate Alzheimer's DiseaseNCT03055741Daehwa Pharmaceutical Co., Ltd.180
终止
2 期
Efficacy and Safety of TD-1473 in Crohn's DiseaseCrohn's DiseaseNCT03635112Theravance Biopharma167
已完成
2 期
A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With RosaceaRosaceaNCT00667173Dow Pharmaceutical Sciences140